GLP-1 Microdosing — What It Is, Who It's For, and What We Know

The practice of taking GLP-1s below standard doses for maintenance, sensitivity, or lower-BMI situations — the rationale, the honest evidence gap, and the safety rails any legitimate protocol uses.

What “microdosing” means here GLP-1 microdosing is the deliberate use of doses below the standard titration ladder — for example, staying at or under a starting dose long-term, or using fractional steps that commercial pens do not offer. It is not a hack or a trend so much as a name for something clinicians quietly do: matching dose to goal when the goal is not maximum weight loss. Three real use cases: 1. Maintenance after reaching goal. The STEP 4 trial showed that continuing semaglutide preserves weight loss while stopping reverses it. But full-dose-forever is expensive and, for some, unnecessarily strong. Many prescribers step maintenance patients down to lower or less frequent doses and hold there as long as weight and appetite stay controlled. 2. High sensitivity. A minority of patients get strong appetite effects — or strong nausea — at the lowest standard steps. Fractional dosing lets them stay in the game instead of quitting. 3. Lower-BMI or relapse-prevention scenarios, such as a patient with a documented history of obesity who has lost weight and is fighting regain. This is off-label, lives outside FDA-labeled indications, and is exactly where strict screening matters most (see the guardrails below). ## Why it is plausible — and what we do not know Dose–response curves from the trial programs show meaningful appetite suppression beginning at the lowest tested doses; 0.25 mg semaglutide was designed as a “non-therapeutic” starter, yet plenty of patients lose weight on it. Pharmacologically, partial receptor activation producing partial effect is unsurprising. What microdosing does not have is its own trial program. Nobody has run a randomized maintenance trial of, say, 0.5 mg semaglutide weekly versus 2.4 mg. So honest framing is: biologically plausible, clinically practiced, formally unproven. Anyone promising specific results from microdosing is ahead of the data. ## Why compounding and microdosing are intertwined Commercial pens come in fixed steps; you cannot dial a Wegovy pen to 0.35 mg. Fractional and in-between doses generally require vial-and-syringe or compounded products — which is why microdose protocols are mostly found at weight-management programs built on compounded GLP-1s. A small number of telehealth programs have formalized this with published microdose protocols — NexLife is the clearest example, with tiered eligibility, documented-history requirements for lower-BMI patients, and mandatory provider review; that formality is a good sign, not a red flag. ## The guardrails a legitimate microdose protocol has - Documented rationale. Maintenance, sensitivity, or relapse prevention — written down, not vibes. Lower-BMI use should require documented history (e.g., prior obesity or prior GLP-1 response). - Eating-disorder screening with teeth. Sub-threshold dosing must never become a tool for people whose BMI is already healthy-to-low and falling; a BMI floor (typically 18.5) and active-ED exclusion are standard. - A ceiling and a re-qualification rule. Escalating beyond the microdose range should push you back into standard-protocol eligibility, not happen by drift. - Cosmetic-use refusal. “I want to lose ten vanity pounds” is not an indication, and programs willing to prescribe for it will cut other corners too. ## The bottom line Microdosing is a legitimate, conservative-minded practice for maintenance and sensitivity — with an honest evidence gap and real potential for misuse at the low-BMI end. If you pursue it, do it inside a program with the guardrails above, not by stretching doses yourself; under-dosed DIY stretching of pens also tends to under-deliver and disappoint. Related reading: dosing and titration and will I regain weight if I stop?